Partner Value Proposition

Everyone's an AI expert
until it's time to build.

Ethan Oppenheim | 2013 Deloitte Lifer

Scroll
01 — The Forward-Deployed Mindset

Consulting has to evolve

The consulting model is shifting. Clients don’t need a diagnosis and a deck, they need someone who can understand the problem and build a solution on the spot. That’s the forward-deployed mindset, and I’ve been operating this way since 2013, rapidly building custom accelerators, demoing them to clients before an RFP ever exists, and turning live products into sole-sourced projects. For years, that made me the edge case. Now it’s how all of us must operate.

02 — The Case for Life Sciences Access
Start where the stakes are highest
Market Access
Patient Services
AI & Data
01
Market Access

The most complex problem in pharma

Getting therapies to patients through payers, pricing regulations, and reimbursement systems is where surface-level understanding falls apart. The problems are too nuanced, the data too messy, the stakes too high. This is not a space where generic AI solutions work. It demands deep domain expertise built over years of working inside these organizations, understanding the regulations, the data structures, and the commercial pressures that drive every decision. I have built in this space across every technology wave: analytics platforms, ML models, and now generative and agentic AI. Each generation made the solutions more powerful, but only because the domain expertise was already there.

02
Patient Services

Where the impact lands

The ultimate measure of success in life sciences is whether therapies reach the patients who need them. Patient services, from hub operations and copay programs to specialty pharmacy coordination, is where strategy becomes reality. I have built solutions across this value chain that connect the dots between commercial strategy and patient outcomes: platforms that track patient journeys, analytics that optimize program performance, and AI tools that predict and close gaps in access. When Market Access opens the door, Patient Services walks patients through it.

03
AI & Data

The engine that makes it all faster

AI is not the destination. It is the accelerant. Every solution I build is powered by a technical foundation that has evolved with each wave: from Tableau-driven analytics factories to predictive ML models to the generative and agentic AI systems we deploy today. The difference is not just knowing how to use the technology. It is knowing how to architect, build, and ship production-grade AI products that solve real commercial problems. While others present frameworks and roadmaps, we walk into the room with a working product the client can interact with from the first meeting.

03 — The Network

Bring the right people together

Market Access is where the strategy lives — navigating payers, pricing, and reimbursement in one of pharma's most complex spaces. Patient Services is where the impact lands — connecting therapies to the people who need them. AI & Engineering is what makes it all faster, smarter, and scalable. The value is in being the bridge across all three — and in the multi-disciplinary network that makes it possible.

04 — Track Record

To go from demos to deals

$[XX]M
Total Revenue
$[XX]M
Current Pipeline
Pfizer J&J Amgen Takeda Teva Eli Lilly Gilead AbbVie Roche Abbott AstraZeneca Astellas Merck Vertex
[XX]+
Accelerators Built
[XX]
In Development
Contract ExplorationQuickly talk to your contracts with AI for terms analysis, enhancing negotiations and reducing errors Contract Performance & Monitoring AnalyticsComprehensive Post-Deal analytics for insights into customer contract performance to ensure adherence to commitments and support future deal negotiations Pricing AnalyticsConvergeHEALTH Pricing Analytics for market access pricing strategy and optimization Drug Price TransparencyUse mandated price transparency data to analyze negotiated reimbursement rates for medical benefits Customer Master ManagementAutomate data integration and roster updates to enable scalable, error-free membership management and reduce revenue leakage Access & Discontinuation Risk ModelingPredict patient access barriers by analyzing disparate data sources (SPP, HUB, longitudinal APLD, copay, Social Determinants of Health, etc.) Policy Horizon ScanningAutomate evaluation of Part B and D drugs on the CMS spend dashboard to identify candidates for MFP negotiations Policy InsightsGenerate insights from CMS guidance, IRA statutes, and historic negotiations to prepare for drug price negotiations Program CoachOrchestration hub to coach users for IRA readiness efforts, from selection to negotiation and effectuation IPAY Manufacturer Triage AgentAgentic solution to automate triaged GFIs that require Manufacturer clarification Formulary ValidationAutomate validation of payer submitted rebate claims against contracted and actual formulary positions Copay Voucher OptimizationOptimize program investment by identifying providers and patient cohorts at risk of non-adherence Script ProfitabilityIdentify script profitability opportunities across copay and rebate programs Systematic Literature ScansStrengthen market access literature scans with automated data extraction and synthesis Global Value Dossier AuthoringGenerate value reports that integrate global data to facilitate GVD authoring, standardize submissions, and support market access across regions Access Strategy / PICO SimulationAutomate analysis of HTA reports and reimbursement data to identify evidence packages driving optimal outcomes in evaluations, decisions, and pricing

What Clients & Leaders Are Saying

"We chose Deloitte because Ethan showed up with a working AI prototype, while others showed up with slides."

Larry Ken-Kwofie
Pfizer | Sr. Director, Market Access

"These demos are light-years ahead of what everyone else has shown us is possible with AI."

Lili Ferguson-LaChance
Amgen | Exec. Director, US V&A Strategy

"I'm trying to get everyone to do what Ethan is doing. I need him to show them all how."

Caleb Longenberger
Deloitte | Pfizer & Eli Lilly LCSP

The Case for Partnership

Ethan Oppenheim  |  2013 Deloitte Lifer  |  Market Access AI Practice Lead

Domain + Execution

  • + 12 years building next-gen solutions across every technology wave: Tableau, ML, GenAI, and now agentic AI
  • + Deep domain expertise in Market Access, one of pharma's most complex problem spaces
  • + Does not advise on AI. Builds it, sells it, and delivers it faster than the competition
  • + Clients choose Deloitte before an RFP drops because he walks in with a working product

Network

  • + Multi-disciplinary network spanning Market Access, Patient Services, and AI & Data
  • + The engine behind go-to-market orchestration, pursuit staffing, and bringing the best of Deloitte to every engagement

Track Record

  • + 30+ sole-sourced projects at Pfizer through embedded delivery model
  • + Products commercialized into ConvergeHEALTH (Pricing Analytics, Deal Analytics, Patient Connect)
  • + Industry-standard CPMA platform adopted across Pfizer, Amgen, Celgene, Roche, and Merck
  • + Portfolio of agentic life science accelerators now brought to market across 12+ accounts

The Opportunity

  • + Market Access is the highest-value, most underserved space for AI in life sciences
  • + Leading the practice that transforms how Deloitte wins and delivers AI-powered work
  • + Every firm is talking about AI. This is the partner who has already shipped it.

Everyone is an AI expert until it is time to build.
Ethan builds it, sells it, delivers it, and has the track record to prove it.